Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...
Medicare drug plans can now cover Eli Lilly's blockbuster obesity drug Zepbound for obstructive sleep apnea, the Centers for Medicare & Medicaid Services confirmed to CNBC. That opens the door for ...
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, ...
The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...
The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...
When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously ...
In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.